Whereas low-count MBL hardly ever progresses to CLL, higher-rely MBL progresses to CLL requiring therapy at a price of one% to two% a year. Significant-depend MBL is distinguished from Rai 0 CLL dependant on whether or not the B-cell depend is above or below 5 × 109/L. Though individuals with both of those superior-depend MBL and CLL Rai phase 0 a